Loading...

Navidea Biopharmaceuticals

DB:NO1
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NO1
DB
$36M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The last earnings update was 36 days ago. More info.


Add to Portfolio Compare Print
  • Navidea Biopharmaceuticals has significant price volatility in the past 3 months.
NO1 Share Price and Events
7 Day Returns
-7.9%
DB:NO1
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-
DB:NO1
-10.2%
DE Biotechs
-6%
DE Market
NO1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Navidea Biopharmaceuticals (NO1) -7.9% 41% - - - -
DE Biotechs -2.4% 1.8% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.2% 7.4% -6% 10.1% 15.4%
1 Year Return vs Industry and Market
  • No trading data on NO1.
  • No trading data on NO1.
Price Volatility
NO1
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Navidea Biopharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Navidea Biopharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €0.117.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Navidea Biopharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Navidea Biopharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:NO1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.09
AMEX:NAVB Share Price ** AMEX (2019-04-18) in USD $0.18
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Navidea Biopharmaceuticals.

DB:NO1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AMEX:NAVB Share Price ÷ EPS (both in USD)

= 0.18 ÷ -0.09

-1.9x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Navidea Biopharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Navidea Biopharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Navidea Biopharmaceuticals's expected growth come at a high price?
Raw Data
DB:NO1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.9x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Navidea Biopharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Navidea Biopharmaceuticals's assets?
Raw Data
DB:NO1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.01
AMEX:NAVB Share Price * AMEX (2019-04-18) in USD $0.18
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.84x
DB:NO1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AMEX:NAVB Share Price ÷ Book Value per Share (both in USD)

= 0.18 ÷ 0.01

20.69x

* Primary Listing of Navidea Biopharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Navidea Biopharmaceuticals is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Navidea Biopharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Navidea Biopharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Navidea Biopharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Navidea Biopharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.5%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Navidea Biopharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Navidea Biopharmaceuticals's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Navidea Biopharmaceuticals's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Navidea Biopharmaceuticals's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:NO1 Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:NO1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:NO1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 1 4 -16
2018-09-30 1 4 -19
2018-06-30 1 5 -17
2018-03-31 2 -11 -18
2017-12-31 2 59 -14
2017-09-30 2 63 -10
2017-06-30 4 67 -10
2017-03-31 5 73 -8
2016-12-31 5 4 -7
2016-09-30 8 -3 -9
2016-06-30 10 -10 -15
2016-03-31 12 -17 -24

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Navidea Biopharmaceuticals is high growth as no earnings estimate data is available.
  • Unable to determine if Navidea Biopharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:NO1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Navidea Biopharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NO1 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.09
2018-09-30 -0.12
2018-06-30 -0.10
2018-03-31 -0.11
2017-12-31 -0.08
2017-09-30 -0.06
2017-06-30 -0.06
2017-03-31 -0.05
2016-12-31 -0.05
2016-09-30 -0.05
2016-06-30 -0.10
2016-03-31 -0.16

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Navidea Biopharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Navidea Biopharmaceuticals's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Navidea Biopharmaceuticals's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Navidea Biopharmaceuticals's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Navidea Biopharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Navidea Biopharmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Navidea Biopharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Navidea Biopharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Navidea Biopharmaceuticals does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Navidea Biopharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Navidea Biopharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Navidea Biopharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Navidea Biopharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NO1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1.17 -16.16 6.60 4.22
2018-09-30 1.45 -19.16 10.57 5.12
2018-06-30 1.44 -16.88 8.42 4.76
2018-03-31 1.51 -17.60 9.31 4.81
2017-12-31 1.81 -13.73 10.69 4.51
2017-09-30 2.45 -9.67 8.33 4.89
2017-06-30 4.05 -9.90 9.59 4.94
2017-03-31 4.60 -7.56 8.31 5.77
2016-12-31 4.97 -7.38 7.92 7.14
2016-09-30 8.23 -8.53 9.60 7.62
2016-06-30 10.39 -14.84 11.74 10.60
2016-03-31 12.09 -23.71 14.40 10.88
2015-12-31 3.01 -23.09 10.89 10.56
2015-09-30 11.15 -31.96 17.10 11.90
2015-06-30 9.42 -30.79 15.81 12.15
2015-03-31 7.63 -31.32 16.67 14.97
2014-12-31 2.05 -30.36 9.53 15.12
2014-09-30 4.61 -42.61 15.49 23.91
2014-06-30 2.76 -47.02 16.81 26.03
2014-03-31 1.88 -47.10 16.07 25.30
2013-12-31 1.13 -42.70 15.53 23.71
2013-09-30 0.60 -36.15 14.20 18.64
2013-06-30 0.20 -33.97 13.17 18.83
2013-03-31 0.07 -29.53 11.97 16.93
2012-12-31 0.08 -29.20 11.18 16.89
2012-09-30 0.07 -29.58 10.94 19.54
2012-06-30 0.33 -21.54 10.06 16.93

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Navidea Biopharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Navidea Biopharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Navidea Biopharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Navidea Biopharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Navidea Biopharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Navidea Biopharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Navidea Biopharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Navidea Biopharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Navidea Biopharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Navidea Biopharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 17.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Navidea Biopharmaceuticals Company Filings, last reported 3 months ago.

DB:NO1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 2.41 0.32 4.28
2018-09-30 2.01 2.16 6.51
2018-06-30 2.79 2.20 5.49
2018-03-31 4.95 2.28 2.21
2017-12-31 12.05 2.35 4.59
2017-09-30 16.02 1.98 6.62
2017-06-30 17.34 2.00 7.63
2017-03-31 22.37 2.10 13.44
2016-12-31 -67.67 61.60 1.54
2016-09-30 -63.77 62.20 0.81
2016-06-30 -63.91 61.17 1.16
2016-03-31 -57.16 60.85 5.48
2015-12-31 -53.84 61.08 7.17
2015-09-30 -51.82 61.28 11.37
2015-06-30 -44.62 59.17 15.79
2015-03-31 -35.36 35.40 4.88
2014-12-31 -29.80 33.83 5.48
2014-09-30 -31.26 32.48 10.39
2014-06-30 -23.84 31.22 17.47
2014-03-31 -14.61 30.94 26.01
2013-12-31 -4.01 27.67 32.94
2013-09-30 8.86 27.78 44.63
2013-06-30 -1.83 27.31 25.64
2013-03-31 -2.72 13.01 9.85
2012-12-31 -1.41 9.69 9.12
2012-09-30 2.75 6.02 11.21
2012-06-30 9.93 6.57 16.95
  • Navidea Biopharmaceuticals's level of debt (13.1%) compared to net worth is satisfactory (less than 40%).
  • Navidea Biopharmaceuticals had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Navidea Biopharmaceuticals has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Navidea Biopharmaceuticals has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -32.3% per year.
X
Financial health checks
We assess Navidea Biopharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Navidea Biopharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Navidea Biopharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Navidea Biopharmaceuticals dividends.
If you bought €2,000 of Navidea Biopharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Navidea Biopharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Navidea Biopharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:NO1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Navidea Biopharmaceuticals has not reported any payouts.
  • Unable to verify if Navidea Biopharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Navidea Biopharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Navidea Biopharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Navidea Biopharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Navidea Biopharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Navidea Biopharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Navidea Biopharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jed Latkin
COMPENSATION $639,875
AGE 44
TENURE AS CEO 0.7 years
CEO Bio

Mr. Jed A. Latkin is Chief Executive Officer of Navidea Biopharmaceuticals, Inc. since October 1, 2018. He has been Chief Financial Officer, Chief Operating Officer, Treasurer and Secretary of Navidea Biopharmaceuticals, Inc. since April 21, 2016 and serves as its Principal Accounting Officer. He was Interim Chief Executive Officer of Navidea Biopharmaceuticals, Inc. since August 14, 2018 until October 1, 2018. He is Director of Navidea Biopharmaceuticals, Inc. since August 14, 2018. Mr. Latkin has been responsible for a large diversified portfolio of asset based investments in varying industries including product manufacturing, agriculture, energy and healthcare. Mr. Latkin has served as Chief Financial Officer of Viper Powersports, Inc., Chief Executive Officer of End of Life Petroleum Holdings, LLC, Chief Executive Officer of Black Elk Energy, LLC, Portfolio Manager of Precious Capital, LLC and Chief Financial Officer of West Ventures, LLC. He served as Principal Executive Officer of Navidea Biopharmaceuticals, Inc. from May 17, 2016 to September 22, 2016. Prior to his position at Nagel Avenue Capital, LLC, he was a Senior Research Analyst, Global Markets for ING Investment Management and held various finance roles at Troika Dialog, Morgan Stanley, Fleet Boston Robertson Stephens and Citicorp Securities. Mr. Latkin served as Portfolio Manager of Asset Based Lending of Platinum Partners Value Arbitrage Fund L.P. since 2010 and was responsible for a large diversified portfolio of asset based investments in varying industries including product manufacturing, agriculture, energy, healthcare and consumer discretionary. Mr. Latkin has more than 20 years of experience in the financial industry supporting many investments in major markets including biotechnology and pharmaceuticals by providing executive direction and preserving operational control during transitional periods. Mr. Latkin was employed at Nagel Avenue Capital, LLC since 2010. He serves on the boards of the Renewable Fuels Association and Buffalo Lake Advanced Biofuels. He served as a Director of Viper Powersports Inc. from August 23, 2012 to March 6, 2013. Mr. Latkin has a BA from Rutgers University and an MBA from Columbia Business School.

CEO Compensation
  • Jed's compensation has been consistent with company performance over the past year.
  • Jed's remuneration is higher than average for companies of similar size in Germany.
Management Team

Jed Latkin

TITLE
CEO, COO
COMPENSATION
$640K
AGE
44
TENURE
0.7 yrs

Michael Rosol

TITLE
Chief Medical Officer
COMPENSATION
$223K
TENURE
0.3 yrs

Erika Gibson

TITLE
Director of Finance & Administration

William Regan

TITLE
Chief Compliance Officer
COMPENSATION
$263K
AGE
66

Sharon Correia

TITLE
Senior Director of Corporate Communications
Board of Directors Tenure

Average tenure and age of the Navidea Biopharmaceuticals board of directors in years:

0.5
Average Tenure
53
Average Age
  • The average tenure for the Navidea Biopharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Y. Rice

TITLE
Chairman of the Board
COMPENSATION
$101K
AGE
53

Jed Latkin

TITLE
CEO, COO
COMPENSATION
$640K
AGE
44
TENURE
0.7 yrs

Claudine Bruck

TITLE
Director
COMPENSATION
$76K
AGE
63
TENURE
1.1 yrs

Adam Cutler

TITLE
Director
COMPENSATION
$4K
AGE
43
TENURE
0.3 yrs

Siamon Gordon

TITLE
Member of Scientific Advisory Board

Charles Mills

TITLE
Member of Scientific Advisory Board

Sarah Rouan

TITLE
Director
COMPENSATION
$4K
AGE
55
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Navidea Biopharmaceuticals insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
25. Mar 19 Buy John Scott Individual 22. Mar 19 22. Mar 19 357,143 €0.12 €44,270
X
Management checks
We assess Navidea Biopharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Navidea Biopharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. In addition, the company offers NAV4694, a fluorine-18 labeled PET imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimer’s disease and mild cognitive impairment. Further, the company is developing diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.

Details
Name: Navidea Biopharmaceuticals, Inc.
NO1
Exchange: DB
Founded: 1983
$32,105,745
200,590,700
Website: http://www.navidea.com
Address: Navidea Biopharmaceuticals, Inc.
4995 Bradenton Avenue,
Suite 240,
Dublin,
Ohio, 43017,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AMEX NAVB Common Stock NYSE MKT LLC US USD 10. Nov 1992
DB NO1 Common Stock Deutsche Boerse AG DE EUR 10. Nov 1992
Number of employees
Current staff
Staff numbers
17
Navidea Biopharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/20 20:32
End of day share price update: 2019/04/18 00:00
Last earnings filing: 2019/03/15
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.